



COMPANY OVERVIEW

PolarityTE is a commercial-stage biotechnology and regenerative biomaterials company focused on transforming the lives of patients by discovering, designing and developing a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering and material sciences. The PolarityTE platform technology begins with a small piece of the patient's own, or autologous, healthy tissue, rather than artificially manipulated individual cells. From this small piece of healthy autologous tissue, the company creates an easily deployable, dynamic and self-propagating product designed to enhance and stimulate the patient's own cells to regenerate the target tissues. Rather than manufacturing with synthetic and foreign materials within artificially engineered environments, PolarityTE manufactures with the patient's own tissue and uses the patient's own body to support the regenerative process to create the same tissue from which it was derived. PolarityTE's innovative method is intended to promote and accelerate growth of the patient's tissues to undergo a form of effective regenerative healing.

RECENT NEWS

PolarityTE, Inc. Announces the Addition of Ramses Erdtmann, Managing Partner at Point Sur Investors and Former Executive at Pharmacyclics, and David Seaburg, Managing Director at Cowen and CNBC Contributor, to the Board of Directors

Aug 9 2018, 8:30 AM EDT

PolarityTE, Inc. Announces Alain Adam as Vice President of Sales

Jul 31 2018, 8:00 AM EDT

STOCK OVERVIEW

Symbol	COOL
Exchange	Nasdaq
Shares OS	21,304,370
Market Cap	\$562.01M
Last Price	\$26.38
52-Week Range	\$15.21 - \$41.220001

INVESTOR RELATIONS

Rich Haerle
VP of Investor Relations & Corporate Strategy
T: 385-831-5284
ir@polarityte.com

MANAGEMENT TEAM

Denver Lough, M.D., Ph.D.

Chairman of the Board, President, Chief Executive Officer, Chief Scientific Officer

Edward Swanson, M.D.

Executive Vice President & Chief Operating Officer

John Stetson

Executive Vice President and Chief Investment Officer

Paul Mann

Chief Financial Officer

Michael W. Neumeister, MD, FRCS, FACS

Chief Medical Officer

Cameron Hoyler, J.D.

Chief Legal Officer & General Counsel

Jennifer Burdman, J.D.

Chief Intellectual Property Officer and Deputy General Counsel

Stephen Milner, MD, BDS, DSc, FRCSE, FACS

Chief Clinical Officer

Maurice Nahabedian, MD, FACS

Chief Surgical Officer

Holly Kramen, J.D.

Chief Compliance Officer and Privacy Officer

POLARITYTE™, INC.

1960 S 4250 W
Salt Lake City, UT 84104

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.

